Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: Vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study

Breast

Volumn 12, Issue 3, 2003, Pages 208-211

  Elling, D ^a   Eggemann, H ^c   Kummel S ^b   Breitbach, P ^c   Kohls, A ^c   Morack, G ^c   Schlosser, H ^c   Krocker, J ^c  

^a MARTIN LUTHER KRANKENHAUS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE

Author keywords

Adjuvant chemotherapy; Breast cancer; Paclitaxel; Vinorelbin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OUTPATIENT CARE; PAIN; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMATITIS; THROMBOCYTOPENIA;

EID: 0037941471     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00010-9     Document Type: Article

References (14)

1. Bonadonna G. Current, future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute. Eur J Cancer 1996; 32A(2): 209-214.
2. Bonadonna G, Gianni L, Santoro A et al. Drugs ten years later: epirubicin. Ann Oncol 1993; 4: 359-369.
3. Canobbio L, Boccardo F, Pastorino G et al. Phase II study of Navelbine® in advanced breast cancer. Semin Oncol 1989; 16 (Suppl 4): 33-36.
4. Fumoleau P, Delgado F M, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-1252.
5. Garcia-Conde J, Lluch A, Martin M et al. Phase II trial of weekly iv vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5(9): 854-857.
6. Bruno S, Puerto L, Mickiewicz et al. Phase II study of weekly vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. Am J Clin Oncol 1995; 18: 392-396.
7. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997; 24(4 Suppl 10): S10-3-S10-10.
8. Hudis C, Seidman A, Raptis G et al. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1996; 23(1 Suppl 1): 58-64.
9. Omrod D, Holm K, Goa K, Spencer C. Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer. Drugs Aging 1999; 15(5): 389-416.
10. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence finding study. J Clin Oncol 1995; 13(11): 2688-2699.
11. Gehl J, Boesgaard T, Paaske B et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687-693.
12. Conte P F, Baldini E, Gennari A et al, Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 7: 2510-1517.
13. Lück H J, Thommsen C, duBois A et al. Phase II study of paclitaxel and epirubicin as first line therapy in patients with metastatic breast cancer. Semin Oncol 1997; 5(Suppl 17): 17-35.
14. Henderson I C, Berry D, Demetri G et al. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node positive primary breast cancer (bC) [Abstract]. Proc Am Soc Clin Oncol 1998; 17: 390A.